毕 艳

文章来源:南京大学医学院发布时间:2017-12-05浏览次数:26

南京大学医学院博(硕)士研究生导师简介

姓名

毕艳

研究方向:

内分泌代谢病

联系方式

电话:(02583304616-61436

Email: biyan@nju.edu.cn

学术兼职:

中华医学会糖尿病学分会青年委员会,副主任委员

中华医学会糖尿病学分会肥胖与糖尿病学组,副组长

江苏省医学会糖尿病学分会,副主任委员

个人简介

  1. 工作简历

医学博士,主任医师,博士生导师,内分泌科副主任,鼓楼区人大代表,入选江苏省医学重点人才,江苏省333高层次人才培养工程,江苏省六大人才高峰,国之名医青年新锐。

鼓楼医院内分泌科临床和学术影响力不断提升,先后入选国家临床重点专科、江苏省医学重点学科、南京市临床医学中心,复旦榜2017年度最佳内分泌专科排行榜获提名单位第4名(江苏排名第一位)。

  1. 科研情况简介

研究集中于糖尿病和肥胖的临床与基础研究,取得多项原创性成果,在J Autoimmunity, Diabetologia等杂志发表SCI论文51篇。主持省部级等科研项目15项,其中国家自然科学基金4项,总经费700万,在美国、欧洲、澳洲糖尿病年会等国际会议大会报告8相关研究获江苏省科学技术二等奖、江苏省卫生厅新技术引进一等奖、中国糖尿病十大研究最具影响力研究奖,中国胰岛素分泌研究新星奖,中华糖尿病杂志优秀论文一等奖。

  1. 研究兴趣

  1. 2型糖尿病

  2. 肥胖

代表性论文

  1. Ling Q*, Lu J*, Li JJ, Xu QY, Zhu DL, Bi Y(共同通讯). Risk of beta-cell antoimmunity presence of progression to type 1 diabetes: a systemic review and meta-analysis. J Autoimmu, 2017, online.

  2. Feng WH*, Wang HD*, Zhang PZ, Gao CX, Tao JX, Ge ZJ, Zhu DL,Bi Y(共同通讯). Modulation of gut microbiota contributes to curcumin-mediated attenuation of hepatic steatosis in rats. BBA-Gen subjects, 2017, 1861(7): 1801-1812.

  3. Tang SYY*, Wu WJ*, Tang WJ, GeZJ, Hong T, Zhu DL, Bi Y(共同通讯). Suppression of Rho-kinase 1 is responsible for insulin regulation of the AMPK/SREBP-1c pathway in skeletal muscle cells exposed to palmitate.Acta Diabetol, 2017, 54(7):635-644.

  4. Zhang PZ*, Lu J*, Jing YL*, Tang SYY, Zhu DL, Bi Y共同通讯. Global epidemiology of diabetic foot ulceration. Ann Med, 2017, 49(2):106-116.

  5. Tang WJ, Tang SYY, Wang HD, Ge ZJ, Zhu DL, Bi Y(共同通讯). Insulin restores UCP3 activity and decreases energysurfeit to alleviate lipotoxicity in skeletal muscle.Int J Mol Med,2017, online.

  6. Zhang H, Ge ZJ, Tang SYY, Meng R, Bi Y共同通讯), Zhu DL. Erythropoietin ameliorates PA-induced insulin resistance through IRS/AKT/FOXO1, GSK-3β signaling pathway and inhibits inflammatory response in HepG2 cells. Mol Med Rep, 2017, 16(2):2295-2301.

  7. Gu TW*, Zhou WH*,Sun J, Wang J, Zhu DL, Bi Y(共同通讯). Gender and age differences in lipid profile among Chinese adults in Nanjing: a retrospective study of over 230,000 individuals. Exp Clin Endocrinol Diabetes, 2017, online.

  8. Lu Y*, Li P*, Gan WD*, Xu QY, Zhao XZ, Shen SM, Feng WH, Bi Y*共同通讯), Guo HQ*, Zhu DL*. Clinical and pathological characteristics of hypertensive and normotensive adrenal pheochromocytomas. Exp Clin Endocrinol Diabetes, 2016, 124 (6): 372-379.

  9. Tang W, Xu QHong T, Tong G, Feng WShen SBi Y*共同通讯), Zhu D*. Comparative efficacy of anti-diabetic agents on nonalcoholic fatty liver disease in patients with type 2diabetes mellitus: A systematic review and meta-analysis of randomized and non-randomized studies. Diabetes Metab Res Rev, 2016, 32(2): 200-216.

  10. Ge ZJ, Zhang PZ, Hong T, Meng R, Bi Y*共同通讯), Zhu DL*. Erythropoietin via PPAR-dependent AKT activation alleviates hepatic insulin resistance. Sci Rep, 2015, 5: 17878.

  11. Xu W, Bi Y共同第一), Sun ZL, Li J, Guo LX, Yang T, Wu G, Shi LX, Feng ZP, Qin L, Guo XH, Luo ZJ, Lu JM, Shan ZY, Yang WY, Ji QH, Yan L, Li H, Yu XF, Li SQ, Zhou ZG, Lv XF, Liang Z, Lin SD, Zeng LY, Yan JH, Ji LN, Weng JP. Comparison of the effects on glycaemic control and β-cell function in newly diagnosed type 2diabetes patients treated with exenatide, insulin or pioglitazone:a multicentrerandomized parallel-group trial(the CONFIDENCE study). J Intern Med, 2015, 277(1):137-150.

  12. Wu WJ, Tang SYY, Shi JF, Yin WW, Cao S, Bu RF, Zhu DL, Bi Y共同通讯. Metformin attenuates palmitic acid-induced insulin resistance in L6 cells through the AMP-activated protein kinase/sterol regulatory element-binding protein-1c pathway. Int J Mol Med,2015, 35(6): 1734-1740.

  13. Ge ZJ, Zhang PZ, Bi Y共同第一), Li CL, Yang HJ, Zhu DL. Elevated Plasma level of Pigment Epithelium-Derived Factor in type 2 diabetic patients is reduced by metformin treatment in association with weight loss.J Diabetes, 2015, 7(5):740-2.

  14. Bi Y第一兼共同通讯), Wu WJ, Shi JF, Liang H, Yin WW, Chen YY, Tang SYY, Cao S, Cai MY, Shen SM, Gao Q, Weng JP, Zhu DL. Role for sterol regulatory elementbinding protein-1c activation in mediating skeletal muscle insulin resistance via repression of rat insulin receptor substrate-1 transcription. Diabetologia, 2014, 57(3): 592-602.

  15. Bi Y, Zhang B, Xu W, Yang HJ, Feng WH, Li M, Tong GY, Shen SM, Wang X, Zhu B, Weng JP, Zhu DL. Effects of exenatide, insulin, and pioglitazone on liver fat content and body fat distributions in drug-naive subjects with type 2 diabetes.Acta Diabetol, 2014, 51(5): 865-873.

  16. Li CL, Yang HJ, Tong GY, Shen SM, Hu Y, Feng WH,Bi Y(共同通讯), Zhu DL. Correlations between A1c, fasting glucose, 2h postload glucose, and β-cell function in the Chinese populations. Acta Diabetol, 2014, 51(4): 601-608.

  17. Bi Y, Tong GY, Yang HJ, Cai MY, Ma JH, Liang J, Xin B, Miao H, Peng ZH, Zhu DL. The effect of metformin on β-cell function in non-obese Chinese subjects with newly diagnosed type 2 diabetes. Diabetes Metab Res Rev, 2013, 29(8): 664-672.

  18. Bi Y, Yan JH, Tang WL, Yang J, Weng JP. Prevalence of hypoglycemia by intensive bedside glucose monitoring among hospitalized patients with diabetes mellitus in China. J Diabetes, 2013, 5(3): 300-301.

  19. Bi Y, Zeng LY, Zhu DL, Yan JH, Zhang YH, Tong GY, Mu PW, Shen SM, Hu Y, Yu QQ, Liang H, Weng JP. Association of β-cell function and insulin sensitivity with fasting and 2h plasma glucose in a large Chinese population. Diabetes Obes Metab, 2012, 14(2), 174-180.

  20. Bi Y, Zhu DL, Jing YL, Hu Y, Feng WH, Shen SM, Tong GY, Shen XJ, Yu TT, Song D, Yang DH. Decreased beta cell function and insulin sensitivity contributed to increasing fasting glucose in Chinese. Acta Diabetol, 2012, 49 (Suppl 1): S51-S58.

  21. Zhang H, Bi Y(co-first authors), Hu CJ, Lu WP, Zhu DL. Association between the Pro12Ala polymorphism of PPAR-γ gene and the polycystic ovary syndrome: A meta-analysis of case–control studies. Gene, 2012, 503(1): 12-17.

  22. Bi Y, Li XB, Yang DZ, Hao YT, Liang H, Zhu DL, Weng JP. Comparative efficacy and safety of long-acting insulin analogs in patients with type 2 diabetes failing on oral therapy: systemic review and meta-analyses. J Diabetes Invest, 2012, 3(3): 283-293.

  23. Jing YL, Sun QM, Bi Y(co-first authors), Shen SM, Zhu DL. SLC30A8 polymorphism and type 2 diabetes risk: Evidence from 27 study groups.Nutr Metab Cardiovasc Dis, 2011, 21 (6): 398-405.

  24. Sun WP, Bi Y(co-first authors),Liang H, Cai MY, Chen X, Zhu YH, Li M, Xu F, Yu QQ, He XY, Ye JP, Weng JP. Inhibition of obesity-induced hepatic ER stress by early insulin therapy in obese diabetic rats. Endocrine, 2011, 39(3):235-241.

  25. Bi Y, Zhu DL, Cheng JL, Zhu Y, Xu N, Cui SW, Li W, Cheng XB, Wang F, Hu Y, Shen SM, Weng JP. The status of glycemic control: a cross-sectional survey in outpatients with type 2 diabetes mellitus across tertiary, secondary and primary hospitals in Jiangsu Province of China. Clin Ther, 2010, 32(5): 973-983.

  26. Bi Y, Cai MY, Liang H, Sun WP, Li XB, Wang CX, Zhu YH, Chen X, Li M, Weng JP. Increased CPT-1 expression and decreased SREBP-1c expression is associated with reduced intramuscular triglyceride accumulation after insulin therapy in high fat diet and streptozotocin induced diabetic rats. Metabolism, 2009, 58(6):779-786.

  27. Liang H, Cai MY, Bi Y(co-first authors), Zhu YH, Yan JH, Weng JP. A single nucleotide polymorphism (SNP) rs2072907 in the adiponutrin gene (ADPN) was not associated with obesity and type 2 diabetes in Chinese Population. Diabetes Res Clin Pract, 2009, 85(3): e37-e39.

  28. Bi Y, Sun WP, Chen X, Li M, Liang H, Cai MY, Zhu YH, He XY, Xu F, Weng JP. Effects of early insulin therapy on nuclear factor kB and cytokine gene expressions in the liver and muscle of fat-fed, streptozocin-treated diabetic SD rats. Acta Diabetol, 2008, 45(3):167-178.

  29. Bi Y, Yan JH, Liao ZH, Li YB, Tang KX, Xue YM, Yang HZ, Li L, Cai DH, Wu G, Zhang F, Lin SD, Xiao ZH, Zhu DL, Weng JP. The prevalence of diabetes in hospitalized patients and inadequate glycemic control among inpatientswith type 2 diabetes in Guangdong province of China. Chinese Med J, 2008, 121(8): 677-681


承担科研项目

  1. ILC1/ILC2细胞免疫特性在脂肪组织纤维化发生发展中的作用及其机制研究,主持,2018-2021,国家自然科学基金面上项目,52

  2. AMPK在胰岛素抑制SREBP-1c活化而改善骨骼肌脂毒性胰岛素抵抗中的作用机制研究,主持,2016-2019,国家自然科学基金面上项目,58

  3. 高脂诱导骨骼肌胰岛素抵抗的分子调控机制研究,主持,2013-2016,国家自然科学基金面上项目,65

  4. 1型糖尿病优化监测与治疗方案的研究及关键新技术推广,分课题负责人,2017-2020,国家重点研发计划,165

  5. 肠道菌群与胰岛素抵抗的关系及其机制研究,主持,2016-2020,江苏省医学重点人才,100

  6. 基于糖尿病分级诊疗体系的标准化数据建设,主持,2016-2019,江苏省重点研发项目社会发展面上项目,80

  7. 二甲双胍抑制Rho激酶-ERK1/2通路改善骨骼肌脂毒性胰岛素抵抗的作用机制研究,主持,2017,白求恩-默克糖尿病研究基金,10

  8. The role of AMPK in insulin inhibition of SREBP-1c activation-induced insulin resistance in skeletal muscle,主持,2016,中国糖尿病英才研究项目10

  9. PEDF2型糖尿病发病中的作用及机制研究,主持,2012-2014,南京市医学重点科技发展项目,20

  10. 2型糖尿病脂肪细胞功能与GLP-1受体激动剂药物疗效的基础与临床研究,主持,2011-2015,江苏省医学重点人才,100

  11. 2型糖尿病早期个体化治疗方案的临床与基础研究,主持,2012江苏省六大人才高峰,3

  12. 骨骼肌脂毒性的分子调控机制研究,主持,2012-2014,中国博士后基金,5

  13. 高脂诱导胰岛素抵抗的调控机制,主持,2013,中央高校基本科研业务费,8

  14. 血小板衍生因子在2型糖尿病发病中的作用机制研究,主持,2011中央高校基本科研业务费,10

  15. SREBP-1c2型糖尿病骨骼肌胰岛素抵抗及脂毒性中的作用及机制研究主持,2009-2011,国家自然科学基金青年基金,19